FINWIRES · TerminalLIVE
FINWIRES

$MRNA

48 stories mentioning MRNAUpdated 17d ago

Every FINWIRES story that references MRNA, newest first.

Wire

Moderna Q1 Loss Widens, Revenue Rises; Reiterates 2026 Revenue Outlook

Moderna (MRNA) reported a Q1 net loss Friday of $3.40 per diluted share, widening from a loss of $2.52 a year earlier.Analysts polled by FactSet expected a loss of $4.45.Revenue for the quarter ended March 31 was $389 million, up from $108 million a year earlier.Analysts surveyed by FactSet expected $236.4 million.For 2026, the company said it continues to target 10% revenue growth year over year. Analysts polled by FactSet expect $2.10 billion.Shares of the company were over 8% higher in Friday premarket activity.Price: $49.71, Change: $+3.85, Percent Change: +8.38%

$MRNA
Wire

Salesforce Says Moderna Selects Agentforce Platform to Consolidate Commercial Operations

Salesforce (CRM) said Tuesday that Moderna (MRNA) has selected its Agentforce Life Sciences platform to consolidate commercial operations worldwide.The platform will combine data, artificial intelligence, and customer interactions across multiple regions into a single system, Salesforce said.The agreement allows the drugmaker to integrate information from different networks to generate real-time insights for cross-channel promotional campaigns, Salesforce said.The software's open architecture will connect various operations to support Moderna in scaling without vendor restrictions, the company added.Price: $182.49, Change: $+2.31, Percent Change: +1.28%

$CRM$MRNA
Sectors

Sector Update: Health Care Stocks Softer Late Afternoon

Health care stocks fell late Monday afternoon with the NYSE Health Care Index easing 0.2% and the State Street Health Care Select Sector SPDR ETF (XLV) losing 0.3%.The iShares Biotechnology ETF (IBB) shed 0.4%.In corporate news, Eli Lilly (LLY) agreed to acquire Ajax Therapeutics for up to $2.3 billion in cash. The deal includes an upfront payment and subsequent payouts based on the achievement of clinical and regulatory milestones. Lilly shares fell 1.6%.HCA Healthcare (HCA) may face pressure through at least H1 as investors rotate toward managed care, although better trends in March and in-line exchange dynamics support the longer-term outlook, RBC Capital Markets said. HCA Healthcare shares rose 3.2%.Organon (OGN) shares jumped 17% after the company agreed to be acquired by India's Sun Pharmaceutical Industries for $14 a share in cash, valuing the company at $11.75 billion.Moderna (MRNA) is facing a patent infringement lawsuit from CureVac, which alleged that Moderna's COVID-19 vaccine Spikevax used its proprietary mRNA technology without authorization, Reuters reported Saturday. Moderna shares fell 4.7%.

$HCA$LLY$MRNA$OGN
Sectors

Sector Update: Health Care Stocks Softer in Afternoon Trading

Health care stocks were lower Monday afternoon with the NYSE Health Care Index easing 0.1% and the State Street Health Care Select Sector SPDR ETF (XLV) decreasing 0.2%.The iShares Biotechnology ETF (IBB) shed 0.2%.In corporate news, Eli Lilly (LLY) said Monday it has agreed to acquire Ajax Therapeutics for up to $2.3 billion in cash. The deal includes an upfront payment and subsequent payouts based on the achievement of clinical and regulatory milestones, the company said. Lilly shares were down 0.5%.Organon (OGN) shares jumped 17% after the company agreed to be acquired by India's Sun Pharmaceutical Industries $14 a share in cash, valuing the company at $11.75 billion.Moderna (MRNA) is facing a patent infringement lawsuit from CureVac, which alleged that Moderna's COVID-19 vaccine Spikevax used its proprietary mRNA technology without authorization, Reuters reported Saturday. Moderna shares were falling 3.3%.Catalyst Pharmaceuticals (CPRX) is being considered as a potential acquisition by Italy's Angelini Pharma, Bloomberg reported. Catalyst shares rose past 6%.

$CPRX$LLY$MRNA$OGN
Commodities

Exchange-Traded Funds, Equity Futures Higher Pre-Bell Wednesday Amid Extended US-Iran Ceasefire

The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.6%, and the actively traded Invesco QQQ Trust (QQQ) was 0.7% higher in Wednesday's premarket activity as US President Donald Trump extended the ceasefire with Iran.US stock futures were also higher, with S&P 500 Index futures up 0.6%, Dow Jones Industrial Average futures advancing 0.5%, and Nasdaq futures gaining 0.7% before the start of regular trading.US mortgage applications rose 7.9% in the week ended April 17 as lower borrowing costs drove gains in both refinancing and purchase activity, Mortgage Bankers Association data showed Wednesday.The Atlanta Fed Business Inflation Expectations survey for April is scheduled for release at 10 am ET, followed by the weekly EIA domestic petroleum inventories report at 10:30 am ET.In premarket activity, bitcoin was up by 4.3%. Among cryptocurrency ETFs, the cryptocurrency fund ProShares Bitcoin Strategy ETF (BITO) was 4.5% higher, Ether ETF (EETH) advanced 4.1%, and Bitcoin & Ether Market Cap Weight ETF (BETH) gained 1.8%.Power Play:IndustrialThe State Street Industrial Select Sector SPDR ETF (XLI) advanced 1%, while the Vanguard Industrials Index Fund (VIS) was up 2% and the iShares US Industrials ETF (IYJ) was inactive.Target Hospitality (TH) stock was down more than 9% before the opening bell, a day after the company said its selling shareholders priced a secondary offering of 7 million shares at $14 apiece for about $98 million in gross proceeds.Winners and Losers:TechnologyThe State Street Technology Select Sector SPDR ETF (XLK) advanced 1%, and the iShares US Technology ETF (IYW) was 1.2% higher, while the iShares Expanded Tech Sector ETF (IGM) was up 1.1%. Among semiconductor ETFs, the State Street SPDR S&P Semiconductor ETF (XSD) increased by 1.8%, while the iShares Semiconductor ETF (SOXX) rose by 1.5%.TE Connectivity (TEL) shares were down more than 5% in Wednesday's premarket activity despite the company delivering strong fiscal Q2 results that beat estimates after CEO Terrence Curtin told Reuters that persistent Middle East conflict could force price hikes to offset rising material costs and supply chain disruptions.Health CareThe State Street Health Care Select Sector SPDR ETF (XLV) advanced 0.3%, the Vanguard Health Care Index Fund (VHT) was up 0.4%, while the iShares US Healthcare ETF (IYH) was flat. The iShares Biotechnology ETF (IBB) was up 0.7%.Moderna (MRNA) stock was down more than 1% premarket, a day after the company said it administered the initial doses to participants in the US and the UK for a phase 3 clinical trial evaluating its experimental mRNA-1018 pandemic flu vaccine.FinancialThe State Street Financial Select Sector SPDR ETF (XLF) advanced 0.3%. Direxion Daily Financial Bull 3X Shares (FAS) was up 1.1%, while its bearish counterpart, Direxion Daily Financial Bear 3X Shares (FAZ), was 0.8% lower.Capital One Financial (COF) shares were down more than 1% pre-bell after the company overnight reported Q1 results that fell short of analyst expectations.ConsumerThe State Street Consumer Staples Select Sector SPDR ETF (XLP) was up 0.1% and the Vanguard Consumer Staples Index Fund ETF Shares (VDC) was 0.4% higher. The iShares US Consumer Staples ETF (IYK) was flat. The State Street Consumer Discretionary Select Sector SPDR ETF (XLY) gained 0.7%. The VanEck Retail ETF (RTH) was down 0.1%, while the State Street SPDR S&P Retail ETF (XRT) increased 0.6%.Alibaba Group (BABA) shares were up more than 1% pre-bell after The Information reported the company and Tencent are in talks to invest in DeepSeek, which is seeking funding at a valuation of over $20 billion.EnergyThe iShares US Energy ETF (IYE) was flat, while the State Street Energy Select Sector SPDR ETF (XLE) was down by 0.1%.NexGen Energy (NXE) stock was up more than 1% before the opening bell after the company said it completed its 2026 winter drill program at the Patterson Corridor East discovery, extending the vertical extent of the high-grade uranium zone by 33% to 550 meters.CommoditiesFront-month US West Texas Intermediate crude oil retreated by 0.4% to $89.29 per barrel on the New York Mercantile Exchange. Natural gas declined by 0.8% to $2.67 per 1 million British Thermal Units. The United States Oil Fund (USO) increased by 0.9%, while the United States Natural Gas Fund (UNG) was 0.4% higher.Gold futures for May were down by 0.4% at $4,812.10 an ounce on the Comex. Silver futures retreated by 1.1% to $79.73 an ounce. SPDR Gold Shares (GLD) was 0.4% lower, and the iShares Silver Trust (SLV) fell by 0.7%.

Dow JonesNasdaq CompositeS&P 500$BABA$BETH$BITO$COF$EEM$EETH$EXI$FAS$FAZ$GLD$IBB$IGM$IGV$IPK$IVV$IWM$IYE$IYH$IYJ$IYK$IYW$MRNA$NXE$PMR$QQQ$RTH$SLV$SOXX$SPY$TEL$TH$UNG$USO$VDC$VHT$VIS$XLE$XLF$XLI$XLK$XLP$XLV$XLY$XRT$XSD
Wire

Moderna Says European Commission Grants Marketing Authorization for mCombriax Vaccine for Influenza, COVID-19

Moderna (MRNA) said Tuesday the European Commission has granted marketing authorization for its mCombriax vaccine for the prevention of influenza and COVID-19 caused by SARS-CoV-2 in individuals 50 years of age and older.The marketing authorization is valid in all 27 European Union member states, as well as Iceland, Liechtenstein and Norway, Moderna said.The Commission's authorization is based on the results from the phase 3 clinical study evaluating the safety, reactogenicity, and immunogenicity of mCombriax in two independent age groups of about 4,000 adults each, Moderna said.Price: $54.02, Change: $-0.57, Percent Change: -1.04%

$MRNA
Wire

Moderna's Investigational Cancer Therapy Shows Promising Early Trial Results

Moderna (MRNA) said Friday that early clinical trial data for its cancer therapy mRNA-4359 showed an 83% overall response rate, building confidence in the treatment's potential.The therapy is being evaluated in combination with pembrolizumab, an immunotherapy drug for various types of cancer, as a first-line treatment for patients with advanced or metastatic melanoma.The company said the US Food and Drug Administration has granted Fast Track designation to the combination for certain patients with advanced melanoma, which could speed up its development and regulatory review.Moderna will present results from the Phase 1/2 study at the American Association for Cancer Research annual meeting, scheduled for April 17 to April 22.Price: $54.50, Change: $-0.18, Percent Change: -0.33%

$MRNA
Wire

Goldman Sachs Adjusts Moderna Price Target to $43 From $41, Maintains Neutral Rating

Moderna (MRNA) has an average rating of Hold and mean price target of $45.21, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $55.38, Change: $+0.70, Percent Change: +1.28%

$MRNA

Showing 41-48 of 48

Track with the FINWIRES app suite